Barclays (LSE: BARC) shares fell on Monday, October 19, after reports that the Bank of England is examining the bank’s handling of certain private credit exposures. The review centres on allegations that derivatives linked to illiquid loans may have been incorrectly classified. Barclays has defended its treatment of the positions.
Bank of England Review Puts Barclays Under Pressure
The Barclays share price came under pressure after the Financial Times reported that the Bank of England’s Prudential Regulation Authority was examining how the lender classified derivatives tied to private credit loans.
The allegations concern total return swaps used to finance loans linked to private credit funds. The concern is that placing these instruments in the trading book rather than the banking book could affect how the associated risks are assessed and how much regulatory capital the bank must hold.
Reuters reported the regulatory scrutiny on October 19. Barclays said the exposures were hedged through matching swaps with other counterparties and should therefore be treated as trading positions. The Bank of England declined to comment.
The report added to pressure on UK bank stocks. London's FTSE 100 was down 0.9% at 10,787.93 points by 0958 GMT, with financial and mining shares among the main drags.
What the Barclays Share Price Drop Means for Investors
Barclays shares fell about 2.6% to 2.7% during the morning session, underperforming the broader UK market. The exact decline varied with the time of the market update.
The immediate concern is whether the regulatory review could lead to changes in how the bank reports its private credit exposures or calculates capital requirements. The available reports do not establish that Barclays breached regulations. The matter remains under scrutiny.
Investors are also watching the bank’s upcoming results. Barclays is scheduled to report its third-quarter earnings on October 22, which could provide further information on performance and risk management.
For investors following UK stocks and broader market developments, the next key signals will be any further information about the regulatory review and the bank’s earnings update. Until more details emerge, the investigation remains a source of uncertainty rather than a confirmed financial impact.